Report #2875186

Received Nov 26, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 76 yrs
State: AZ
Recovered: Unknown
Vaccinated: Nov 21, 2025
Onset: Nov 21, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEPAB	HEP A + HEP B (TWINRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	H7RF2	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

patient that received Twinrix 1st dose in 2015, and the 2nd dose 21-Nov-2025; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 76-year-old female patient who received HAB (Twinrix) (batch number H7RF2, expiry date 17-JAN-2026) for prophylaxis. Previously administered products included Twinrix (received 1st dose in 2015). On 21-NOV-2025, the patient received the 2nd dose of Twinrix. On 21-NOV-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: patient that received Twinrix 1st dose in 2015, and the 2nd dose 21-Nov-2025). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 24-NOV-2025 The vaccine administration facility was the same as primary reporter. :